Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

Milton Maciel Jr; Rama R Amara; Katharine J Bar; Shane Crotty; Steven G Deeks; Christopher Duplessis; Gaurav Gaiha; M Juliana McElrath; Andrew McMichael; Amy Palin; Rachel Rutishauser; Stuart Shapiro; Stephen T Smiley; M Patricia D'Souza

doi:10.1038/s41541-024-00818-y

Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV-workshop report

NPJ Vaccines. 2024 Feb 21;9(1):39. doi: 10.1038/s41541-024-00818-y.

Authors

Affiliations

¹ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
² Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
³ Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA.
⁵ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
⁶ Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
⁷ Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.
⁸ Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁰ Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
¹¹ Department of Medicine, University of California, San Francisco, CA, USA.
¹² Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. pdsouza@niaid.nih.gov.

Abstract

The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), convened a virtual workshop on August 8-9^th, 2023 to explore potential synergies between HIV vaccine approaches that are designed to induce cellular or humoral immune responses. The goal of this workshop was to review data on leading vaccine candidates and to discuss the best strategies for combining these approaches to optimize immunity against HIV. Here, we summarize the findings reviewed at the workshop and discuss the knowledge gaps and priorities for future studies that will help accelerate the development of a preventive HIV vaccine.